Quest Diagnostics (DGX) Cost of Revenue (2009 - 2026)

Quest Diagnostics has reported Cost of Revenue for 18 years, with the latest figure at $2.0 billion in Q2 2026.

• Quarterly Cost of Revenue rose 10.89% year-over-year to $2.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.7 billion (up 9.72% YoY) and the FY2025 annual result came in at $7.4 billion, up 11.19% from the prior year.
• Cost of Revenue rose to $2.0 billion in Q2 2026 per DGX's latest filing, from $2.0 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.0 billion in Q2 2026 and troughed at $1.5 billion in Q3 2023.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2022 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue decreased 8.32% in 2022, then gained 14.12% in 2025.
• Over 5 years, Cost of Revenue stood at $1.6 billion in 2022, then declined by 1.46% to $1.6 billion in 2023, then advanced by 13.6% to $1.8 billion in 2024, then advanced by 7.54% to $1.9 billion in 2025, then increased by 6.33% to $2.0 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.0 billion, $2.0 billion, and $1.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.